BioNTech vaccine: This country could be the first to emerge from the pandemic – but there is criticism


Israel’s renowned Democracy Institute (IDI) has criticized the country’s agreement with corona vaccine manufacturer Pfizer. Institute member Tehilla Shwartz Altshuler said on Monday: “ The  agreement contains one of the most extensive human studies in the 21st century, and Israel’s wealth of data will be available to the rest of the world for scientific research.”

Israel secured a large amount of the vaccine from the manufacturers BioNTech and Pfizer early on. © The  agreement between Israel and Pfizer provides, among other things, for the transmission of vaccination data to the vaccine manufacturer. © The  deal was published on Sunday, but many passages are censored.

Are you interested in the latest trends from the biotechnology industry? ©

 The n register here now and you will find out more shortly.

Shwartz Altshuler said the deal could be seen as an achievement for Israel in its quest to be the first country to emerge from the pandemic. Nevertheless, the so-called Helsinki Committee in Israel, which is responsible for the approval of studies on humans, should have approved this first. Shwartz Altshuler said that one should have obtained the consent of the Israelis to use their health data.

One of the biggest problems with the agreement is that, while it stressed the need to protect Israeli privacy, it did not specify any concrete steps. It is known that the anonymity of big data can be removed. ©

 The refore, the agreement in its current form may violate the protection of the health data of all Israelis.

A little over nine million people live in Israel. A massive vaccination campaign has been running parallel to the third wave for a month. So far, around 2.1 million people in Israel have received a first dose and almost 310,000 people have received a second dose.

Nonetheless, the hope that rests on the BioNTech / Pfizer vaccine is not only great in Israel. People around the world are waiting for production capacities to be increased. And here the two partners are well on their way, as the latest news shows. Accordingly, the BioNTech share can easily pull in on Monday afternoon. On the Tradegate trading platform, there is a good one percent increase. Stick to it!

 The  chairman of the board and majority owner of the publisher Börsenmedien AG, Mr. Bernd Förtsch, has taken direct and indirect positions on the following financial instruments mentioned in the publication or related derivatives that benefit from the publication of any resulting price development: BioNTech.


 The  author holds positions directly on the following financial instruments referred to in the publication or related derivatives that benefit from any price development resulting from the publication: BioNTech.

(With material from dpa-AFX)

[ source link ]

BioNTech vaccine country emerge pandemic criticism


Please enter your comment!
Please enter your name here